€52.75
1.54% yesterday
Madrid, May 20, 05:39 pm CET
ISIN
ES0157261019
Symbol
ROVI
Index
Sector
Industry

Laboratorios Farmaceuticos Target price 2025 - Analyst rating & recommendation

Laboratorios Farmaceuticos Classifications & Recommendation:

Buy
70%
Hold
30%

Laboratorios Farmaceuticos Price Target

Target Price €75.76
Price €52.75
Potential
Number of Estimates 9
9 Analysts have issued a price target Laboratorios Farmaceuticos 2026 . The average Laboratorios Farmaceuticos target price is €75.76. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 7 Analysts recommend Laboratorios Farmaceuticos to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Laboratorios Farmaceuticos stock has an average upside potential 2026 of . Most analysts recommend the Laboratorios Farmaceuticos stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million € 763.75 724.20
7.93% 5.18%
EBITDA Margin 27.07% 26.46%
7.91% 2.24%
Net Margin 17.95% 18.31%
11.53% 2.01%

10 Analysts have issued a sales forecast Laboratorios Farmaceuticos 2025 . The average Laboratorios Farmaceuticos sales estimate is

€724m
Unlock
. This is
5.64% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€751m 2.16%
Unlock
, the lowest is
€703m 8.40%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €764m 7.93%
2025
€724m 5.18%
Unlock
2026
€832m 14.89%
Unlock
2027
€946m 13.67%
Unlock
2028
€1.0b 6.50%
Unlock
2029
€1.1b 5.14%
Unlock

10 Analysts have issued an Laboratorios Farmaceuticos EBITDA forecast 2025. The average Laboratorios Farmaceuticos EBITDA estimate is

€192m
Unlock
. This is
9.23% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€220m 4.12%
Unlock
, the lowest is
€160m 24.22%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €207m 15.21%
2025
€192m 7.29%
Unlock
2026
€241m 25.73%
Unlock
2027
€300m 24.36%
Unlock
2028
€373m 24.62%
Unlock
2029
€417m 11.67%
Unlock

EBITDA Margin

2024 27.07% 7.91%
2025
26.46% 2.24%
Unlock
2026
28.96% 9.45%
Unlock
2027
31.68% 9.39%
Unlock
2028
37.08% 17.05%
Unlock
2029
39.38% 6.20%
Unlock

6 Laboratorios Farmaceuticos Analysts have issued a net profit forecast 2025. The average Laboratorios Farmaceuticos net profit estimate is

€133m
Unlock
. This is
5.03% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€147m 4.94%
Unlock
, the lowest is
€120m 13.92%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €137m 18.54%
2025
€133m 3.26%
Unlock
2026
€168m 26.89%
Unlock
2027
€205m 21.79%
Unlock
2028
€258m 26.04%
Unlock

Net Margin

2024 17.95% 11.53%
2025
18.31% 2.01%
Unlock
2026
20.22% 10.43%
Unlock
2027
21.67% 7.17%
Unlock
2028
25.65% 18.37%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share 2.68 2.59
18.54% 3.36%
P/E 20.35
EV/Sales 3.85

6 Analysts have issued a Laboratorios Farmaceuticos forecast for earnings per share. The average Laboratorios Farmaceuticos EPS is

€2.59
Unlock
. This is
5.13% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
€2.86 4.76%
Unlock
, the lowest is
€2.35 13.92%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €2.68 18.54%
2025
€2.59 3.36%
Unlock
2026
€3.29 27.03%
Unlock
2027
€4.01 21.88%
Unlock
2028
€5.05 25.94%
Unlock

P/E ratio

Current 19.35 27.83%
2025
20.35 5.17%
Unlock
2026
16.03 21.23%
Unlock
2027
13.17 17.84%
Unlock
2028
10.45 20.65%
Unlock

Based on analysts' sales estimates for 2025, the Laboratorios Farmaceuticos stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.63 33.39%
2025
3.85 6.01%
Unlock
2026
3.35 12.96%
Unlock
2027
2.95 12.03%
Unlock
2028
2.77 6.10%
Unlock
2029
2.63 4.89%
Unlock

P/S ratio

Current 3.52 34.83%
2025
3.73 5.98%
Unlock
2026
3.24 12.96%
Unlock
2027
2.85 12.02%
Unlock
2028
2.68 6.10%
Unlock
2029
2.55 4.89%
Unlock

Current Laboratorios Farmaceuticos Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JEFFERIES
Locked
Locked
Locked Apr 07 2025
ALANTRA EQUITIES
Locked
Locked
Locked Mar 25 2025
CAIXABANK BPI
Locked
Locked
Locked Mar 25 2025
ODDO BHF
Locked
Locked
Locked Mar 25 2025
BANCO SANTANDER
Locked
Locked
Locked Mar 24 2025
ANALISIS BANCO SABADELL
Locked
Locked
Locked Mar 04 2025
BANCO SANTANDER
Locked
Locked
Locked Feb 06 2025
Analyst Rating Date
Locked
JEFFERIES:
Locked
Locked
Apr 07 2025
Locked
ALANTRA EQUITIES:
Locked
Locked
Mar 25 2025
Locked
CAIXABANK BPI:
Locked
Locked
Mar 25 2025
Locked
ODDO BHF:
Locked
Locked
Mar 25 2025
Locked
BANCO SANTANDER:
Locked
Locked
Mar 24 2025
Locked
ANALISIS BANCO SABADELL:
Locked
Locked
Mar 04 2025
Locked
BANCO SANTANDER:
Locked
Locked
Feb 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today